Last reviewed · How we verify

NCT04171609

Expressive Writing for Cancer Survivors

Completed NA Last updated 25 August 2020
What this trial tests

NA trial testing Expressive writing in Cancer Survivors in 14 participants. Completed in 14 May 2020.

Timeline
19 July 2019
Primary endpoint
14 May 2020
14 May 2020

Quick facts

Lead sponsorDuke University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment14
Start date19 July 2019
Primary completion14 May 2020
Estimated completion14 May 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Duke University

Who can join

18 and older, any sex, with Cancer Survivors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether a 1-day expressive writing intervention for adult cancer survivors improves resilience scores as measured by the Connor-Davidson Resilience Scale (CD-RISC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Expressive writing

Trials testing the same drug.

Other recruiting trials for Cancer Survivors

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04171609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing